Mi a GBS Inc. (GBS piaci tőkésítése)

GBS Inc. piaci tőkésítése (GBS) $7.05M

GBS Inc. (GBS) Bevétel

Operating across North America and the Asia-Pacific region, GBS Inc. specializes in biosensor diagnostic technology. Its key product is the Saliva Glucose Biosensor, an innovative organic thin-film transistor designed for diabetes management that quantifies glucose levels directly from saliva. The company is also actively advancing a SARS-CoV-2 Biosensor, intended as a supplementary diagnostic tool to existing RNA virus detection tests, and is constructing a broad biosensor platform covering diagnostic modalities such as biochemistry, immunology, tumor markers, hormones, and nucleic acids. GBS Inc. maintains a research agreement with the Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic solutions. Founded in 2016 and headquartered in New York, New York, the company adopted its current name, GBS Inc., in September 2019, having previously operated as Glucose Biosensor Systems (Greater China) Holdings, Inc. It operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.

Év	Bevétel	Változtassa meg
Nincs elég adat a megadott dátumokhoz.

Év

Bevétel

Változtassa meg

Nincs elég adat a megadott dátumokhoz.

Vállalat	Bevétel	Bevételkülönbség	Ország
Abbott Laboratories ABT.US	$46.59B	-	US
Stryker Corporation SYK.US	$25.84B	-	US
Medtronic plc MDT.US	$35.48B	-	IE
Boston Scientific Corporation BSX.US	$21.00B	-	US
Edwards Lifesciences Corporation EW.US	$6.51B	-	US

Vállalat

Bevétel

Bevételkülönbség

Ország